The EU's IP strategy: Enabler or barrier?
EPHA #A2MDialogues
27 October 2020
17:00-18:00
online
Our second dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
How do we ensure that IP incentives compensate and reward innovation but do not distort competition?
What lessons have we learned on IP in the response to COVID19?
Patent-driven innovation may work for profit-driven drug development but it reflects a R&I agenda which favours profit prospects, distortion of competition and market dominance. Additionally, it leads to excessive, unaffordable prices due to monopoly and can stifle meaningful innovation
As the EU prepares to present its IP strategy as well as the scenarios for a review of the legislation on orphan and paediatric medicines, join our experts and key stakeholders who will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition
#A2M Dialogues
Panelists
Alfonso Calles-Sanchez
Policy Officer, DG Internal Market, Industry, Entrepreneurship and SMEs (DG Growth)
European Commission
Dimitri Eynikel
EU Policy & Advocacy Advisor
Médecins Sans Frontières Access Campaign
Sergio Napolitano
General Counsel & External Relations Director
Medicines for Europe
Thyra de Jongh
Principal Consultant
Technopolis Group
Moderated by
Yannis Natsis,
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
Join our panelists to discuss
How should the EU orphans and paediatrics legislation be changed?
Is the system rigged to the detriment of generics and biosimilars?
What would a reform of the EU SPC Regulation look like?
Which alternative business models should be pursued in the fields of AMR and vaccine development?
Register for EPHA’s other A2M Dialogues below
Unleashing meaningful innovation through regulatory reform
19 October 2020
17:00-18:00
Pharma & COVID19: Winners, losers, prospects
19 November 2020
16:00-17:00
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
16:00-17:30
Follow on social media
#A2MDialogues
#A2Msolutions
Contact
Yannis Natsis
Policy Manager, Universal Access and Affordable Medicines, EPHA
yannis@epha.org